TY - JOUR
T1 - Management of hypertensive disorders in pregnancy
T2 - a position statement of the European Society of Hypertension Working Group 'Hypertension in Women'
AU - Thomopoulos, Costas
AU - Hitij, Jana Brguljan
AU - De Backer, Tine
AU - Gkaliagkousi, Eugenia
AU - Kreutz, Reinhold
AU - Lopez-Sublet, Marilucy
AU - Marketou, Maria
AU - Mihailidou, Anastasia S.
AU - Olszanecka, Agnieszka
AU - Pechère-Bertschi, Antoinette
AU - Pérez, Mariana Paula
AU - Persu, Alexandre
AU - Piani, Federica
AU - Socrates, Thenral
AU - Stolarz-Skrzypek, Katarzyna
AU - Cífková, Renata
PY - 2024/7/1
Y1 - 2024/7/1
N2 - Hypertensive disorders in pregnancy (HDP), remain the leading cause of adverse maternal, fetal, and neonatal outcomes. Epidemiological factors, comorbidities, assisted reproduction techniques, placental disorders, and genetic predisposition determine the burden of the disease. The pathophysiological substrate and the clinical presentation of HDP are multifarious. The latter and the lack of well designed clinical trials in the field explain the absence of consensus on disease management among relevant international societies. Thus, the usual clinical management of HDP is largely empirical. The current position statement of the Working Group 'Hypertension in Women' of the European Society of Hypertension (ESH) aims to employ the current evidence for the management of HDP, discuss the recommendations made in the 2023 ESH guidelines for the management of hypertension, and shed light on controversial issues in the field to stimulate future research.
AB - Hypertensive disorders in pregnancy (HDP), remain the leading cause of adverse maternal, fetal, and neonatal outcomes. Epidemiological factors, comorbidities, assisted reproduction techniques, placental disorders, and genetic predisposition determine the burden of the disease. The pathophysiological substrate and the clinical presentation of HDP are multifarious. The latter and the lack of well designed clinical trials in the field explain the absence of consensus on disease management among relevant international societies. Thus, the usual clinical management of HDP is largely empirical. The current position statement of the Working Group 'Hypertension in Women' of the European Society of Hypertension (ESH) aims to employ the current evidence for the management of HDP, discuss the recommendations made in the 2023 ESH guidelines for the management of hypertension, and shed light on controversial issues in the field to stimulate future research.
KW - assisted reproduction
KW - cardiovascular risk
KW - gestational hypertension
KW - hypertension
KW - hypertensive disorders in pregnancy
KW - preeclampsia
KW - pregnancy
KW - pregnancy outcomes
UR - http://www.scopus.com/inward/record.url?scp=85195042327&partnerID=8YFLogxK
U2 - 10.1097/HJH.0000000000003739
DO - 10.1097/HJH.0000000000003739
M3 - Article
C2 - 38690949
AN - SCOPUS:85195042327
SN - 0263-6352
VL - 42
SP - 1109
EP - 1132
JO - Journal of Hypertension
JF - Journal of Hypertension
IS - 7
ER -